Skeletal Muscle Relaxants: Adverse Effects

Nondepolarizing competitive neuromuscular blockers have minimal side effects compared to depolarizing agents like succinylcholine. While nondepolarizing blockers may cause hypotension, depolarizing blockers trigger severe complications including cardiac arrhythmia, postoperative muscle pain, prolonged apnea, and respiratory arrest. The difference stems from their distinct mechanisms of action at the neuromuscular junction.

Patients with mutated cholinesterases cannot metabolize and eliminate succinylcholine properly, leading to delayed muscle recovery. The diaphragm remains paralyzed longer than normal, causing apnea where sedated patients stop breathing. Correct dosing of succinylcholine becomes essential for these at-risk patients to prevent respiratory complications.

Succinylcholine facilitates potassium release from intracellular storage, raising serum levels dangerously. Patients with burns, nerve damage, or kidney failure have already suffered rapid potassium loss and cannot tolerate additional increases. Administering succinylcholine to these patients risks hyperkalemia and cardiac arrest, making avoidance critical for patient safety.

Directly acting muscle relaxants including dantrolene and botulinum toxin cause general muscle weakness and hepatotoxicity. Botulinum toxin additionally causes respiratory tract infections and loss of bladder control. These adverse effects require careful patient monitoring and appropriate dose management to minimize complications.

Centrally acting muscle relaxants induce central nervous system depression with varied symptoms. Tizanidine causes drowsiness, hypotension, dizziness, dry mouth, and hepatotoxicity. Diazepam causes anxiety, tremors, insomnia, and hallucinations. These CNS effects require careful monitoring, especially in vulnerable populations like epileptic or pregnant patients.

Abrupt discontinuation of baclofen, a nondepolarizing blocker, leads to recurrence of spastic conditions. Patients experience return of muscle spasticity and related symptoms. Gradual tapering rather than sudden cessation is recommended to prevent these rebound adverse effects and maintain therapeutic benefit.

Administering appropriate drug doses and avoiding high doses in at-risk populations helps minimize adverse effects. Special caution applies to epileptic patients and pregnant women who face increased severity of side effects. Proper patient selection, dose regulation, and monitoring are essential strategies for safe skeletal muscle relaxant use.